Hepcidin promotes osteogenic differentiation through the bone morphogenetic protein 2/small mothers against decapentaplegic and mitogen‑activated protein kinase/P38 signaling pathways in mesenchymal stem cells

Lu,Huading; Lian,Liyi; Shi,Dehai; Zhao,Huiqing; Dai,Yuhu

doi:10.3892/mmr.2014.2769

Hepcidin promotes osteogenic differentiation through the bone morphogenetic protein 2/small mothers against decapentaplegic and mitogen‑activated protein kinase/P38 signaling pathways in mesenchymal stem cells

Authors:
- Huading Lu
- Liyi Lian
- Dehai Shi
- Huiqing Zhao
- Yuhu Dai
View Affiliations

Affiliations: Department of Orthopedics, Third Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510630, P.R. China
Published online on: October 24, 2014 https://doi.org/10.3892/mmr.2014.2769
Pages: 143-150
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The ability of mesenchymal stem cells (MSCs) to differentiate into osteogenic lineages requires management for their future use in treating bone destruction and osteoporosis. Hepcidin is closely associated with bone metabolism, however, it remains to be elucidated whether hepcidin affects osteogenic differentiation in MSCs. The present study demonstrated that hepcidin enhanced osteoblastic differentiation and mineralization, which was manifested by an upregulation in the differentiation markers alkaline phosphatase and osteogenic genes. Furthermore, the expression levels of bone morphogenetic proteins and small mothers against decapentaplegic homologs were concomitantly increased following hepcidin treatment. In addition, the p38 mitogen‑activated protein kinase may be an upstream kinase for osteoblastic differentiation. Thus, hepcidin may be important in the osteogenic differentiation of MSCs and may be considered as a target in the development of therapies for pathological bone loss.

View Figures

View References

1	Kanis JA and Reginster JY: European guidance for the diagnosis and management of osteoporosis in postmenopausal women - what is the current message for clinical practice? Pol Arch Med Wewn. 118:538–540. 2008.PubMed/NCBI
2	Rachner TD1, Khosla S and Hofbauer LC: Osteoporosis: now and the future. Lancet. 377:1276–1287. 2011. View Article : Google Scholar : PubMed/NCBI
3	Ma B, Liu J, Zhang Q, Ying H, AJ, Sun J, Wu D, Wang Y, Li J and Liu Y: Metabolomic profiles delineate signature metabolic shifts during estrogen deficiency-induced bone loss in rat by GC-TOF/MS. PLoS One. 8:e549652013. View Article : Google Scholar : PubMed/NCBI
4	de Lignieres B: Hormone replacement therapy: clinical benefits and side-effects. Maturitas. 23:S31–S36. 1996.PubMed/NCBI
5	Fournier A, Berrino F, Riboli E, Avenel V and Clavel-Chapelon F: Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 114:448–454. 2005. View Article : Google Scholar : PubMed/NCBI
6	Beral V; Million Women Study Collaborators. Bull D, Green J and Reeves G: Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 369:1703–1710. 2007. View Article : Google Scholar : PubMed/NCBI
7	Furness S, Roberts H, Marjoribanks J and Lethaby A: Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 8:CD0004022012.
8	Li GF, Pan YZ, Sirois P, Li K and Xu YJ: Iron homeostasis in osteoporosis and its clinical implications. Osteoporos Int. 23:2403–2408. 2012. View Article : Google Scholar : PubMed/NCBI
9	Weinberg ED: Iron loading: a risk factor for osteoporosis. Biometals. 19:633–635. 2006. View Article : Google Scholar : PubMed/NCBI
10	Valenti L, Varenna M, Fracanzani AL, Rossi V, Fargion S and Sinigaglia L: Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int. 20:549–555. 2009. View Article : Google Scholar : PubMed/NCBI
11	Weinberg ED: Role of iron in osteoporosis. Pediatr Endocrinol Rev. 6:81–85. 2008.
12	Roussou P, Tsagarakis NJ, Kountouras D, Livadas S and Diamanti-Kandarakis E: Beta-thalassemia major and female fertility: the role of iron and iron-induced oxidative stress. Anemia. 2013:6172042013. View Article : Google Scholar : PubMed/NCBI
13	Sun L, Guo W, Yin C, Zhang S, Qu G, Hou Y, Rong H, Ji H and Liu S: Hepcidin deficiency undermines bone load-bearing capacity through inducing iron overload. Gene. 543:161–165. 2014. View Article : Google Scholar : PubMed/NCBI
14	Sun CC, Vaja V, Babitt JL and Lin HY: Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 87:392–400. 2012. View Article : Google Scholar : PubMed/NCBI
15	Mascitelli L and Goldstein MR: Hereditary hemochromatosis, iron, hepcidin, and coronary heart disease. Med Hypotheses. 82:402–403. 2014. View Article : Google Scholar : PubMed/NCBI
16	Zucker S: The swinging pendulum of the anemia of cancer: erythropoietin trumps hepcidin. J Clin Oncol. 29:e422011. View Article : Google Scholar : PubMed/NCBI
17	Canavesi E, Alfieri C, Pelusi S and Valenti L: Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease. World J Nephrol. 1:166–176. 2012. View Article : Google Scholar : PubMed/NCBI
18	Xu Y, Li G, Du B, Zhang P, Xiao L, Sirois P and Li K: Hepcidin increases intracellular Ca2+ of osteoblast hFOB1.19 through L-type Ca²⁺ channels. Regul Pept. 172:58–61. 2011. View Article : Google Scholar : PubMed/NCBI
19	Ku HK, Lim HM, Oh KH, Yang HJ, Jeong JS and Kim SK: Interpretation of protein quantitation using the Bradford assay: comparison with two calculation models. Anal Biochem. 434:178–180. 2013. View Article : Google Scholar : PubMed/NCBI
20	Zhang P, Xu YJ, Zhao DY, Ma Y, Xiao L, Feng YS, Du BC, Qian ZM and Li K: Increased intracellular iron and mineralization of cultured hFOB 1.19 cells following hepcidin activation through ferroportin-1. Saudi Med J. 31:1303–1308. 2010.PubMed/NCBI
21	Lee KW, Yook JY, Son MY, Kim MJ, Koo DB, Han YM and Cho YS: Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway. Stem Cells Dev. 19:557–568. 2010. View Article : Google Scholar : PubMed/NCBI
22	Kim do Y, Kim GW and Chung SH: Nectandrin A Enhances the BMP-Induced Osteoblastic Differentiation and Mineralization by Activation of p38 MAPK-Smad Signaling Pathway. Korean J Physiol Pharmacol. 17:447–453. 2013.PubMed/NCBI
23	Kim do Y, Jung MS, Park YG, Yuan HD, Quan HY and Chung SH: Ginsenoside Rh2(S) induces the differentiation and mineralization of osteoblastic MC3T3-E1 cells through activation of PKD and p38 MAPK pathways. BMB Rep. 44:659–664. 2011.
24	Chamberlain G, Fox J, Ashton B and Middleton J: Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 25:2739–2749. 2007. View Article : Google Scholar
25	Frazer DM, Wilkins SJ, Becker EM, Vulpe CD, McKie AT, Trinder D and Anderson GJ: Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology. 123:835–844. 2002. View Article : Google Scholar : PubMed/NCBI
26	Sasaki Y, Shimonaka Y, Ikuta K, Hosoki T, Sasaki K, Torimoto Y, Kanada H, Moriguchi Y and Kohgo Y: Hepcidin production in response to iron is controlled by monocyte-derived humoral factors. Int J Hematol. 99:12–20. 2014. View Article : Google Scholar : PubMed/NCBI
27	Dai J, Li Y, Zhou H, Chen J, Chen M and Xiao Z: Genistein promotion of osteogenic differentiation through BMP/SMAD5/RUNX2 signaling. Int J Biol Sci. 9:1089–1098. 2013. View Article : Google Scholar : PubMed/NCBI
28	Liao QC, Xiao ZS, Qin YF and Zhou HH: Genistein stimulates osteoblastic differentiation via p38 MAPK-Cbfal pathway in bone marrow culture. Acta Pharmacol Sin. 28:1597–1602. 2007. View Article : Google Scholar : PubMed/NCBI
29	Li GF, Xu YJ, He YF, Du BC, Zhang P, Zhao DY, Yu C, Qin CH and Li K: Effect of hepcidin on intracellular calcium in human osteoblasts. Mol Cell Biochem. 366:169–174. 2012. View Article : Google Scholar : PubMed/NCBI
30	Chen Z, Wu C, Gu W, Klein T, Crawford R and Xiao Y: Osteogenic differentiation of bone marrow MSCs by β-tricalcium phosphate stimulating macrophages via BMP2 signalling pathway. Biomaterials. 35:1507–1518. 2014.
31	Lin L, Valore EV, Nemeth E, Goodnough JB, Gabayan V and Ganz T: Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood. 110:2182–2189. 2007. View Article : Google Scholar : PubMed/NCBI
32	Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, Campagna JA, Chung RT, Schneyer AL, Woolf CJ, Andrews NC and Lin HY: Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 38:531–539. 2006. View Article : Google Scholar : PubMed/NCBI
33	Liu Y, Zheng WK, Gao WS, Shen Y and Ding WY: Function of TGF-beta and p38 MAKP signaling pathway in osteoblast differentiation from rat adipose-derived stem cells. Eur Rev Med Pharmacol Sci. 17:1611–1619. 2013.PubMed/NCBI